Several groups are developing diagnostic viral genome sequencing assays and panels, which promise high sensitivity and additional information on viral origin and spread.
The company is creating a high-throughput NGS test for healthcare workers and the underserved, and to support viral surveillance programs for large employers.
A study of both tissue and blood samples from patients in a small trial found that liquid biopsy may detect putative resistance mutations missed in tissue.
